top of page

Dr. Wei Wang received his MD and PhD degrees from the University of Virginia School of Medicine in Charlottesville, Virginia. He completed his Internal Medicine residency at the Hospital of the University of Pennsylvania. He was a Medical Oncology fellow at the Fred Hutchison Cancer Center and University of Washington in Seattle. He was a recipient of the ASCO Young Investigator Award. His research was also supported by the Susan G. Komen Foundation and the Avon Foundation. He has authored a number of peer-reviewed articles in prestigious journals such as Science, Immunity, Proceedings of the National Academy of Sciences, Journal of Immunology, and Cancer Research. He has a strong interest in targeted and immunotherapy treatments for cancers.


Medical School

  • University of Virginia School of Medicine, 1999

Residency Training

  • Hospital of University of Pennsylvania, 2001


  • Fred Hutchinson Cancer Research Center/University of Washington, 2005

Board Certification

  • Medical Oncology since 2004


  • American Society of Clinical Oncology Young Investigator Award, 2005

  • Avon Foundation Immunotherapy Fellow, 2002-2005

  • Susan G. Komen Foundation Postdoctoral Fellow, 2005

Hospital Appointment

  • Medical Director, Cancer Genetic Risk Assessment Program, California Pacific Medical Center

Selected Publications

  • Wang W, Meadows LR, den Haan JM et al. Human H-Y: the human male specific histocompatibility antigen derived from the SMCY protein. Science 269:1588-90, 1995.

  • Meadows L, Wang W, den Haan JM et al. The HLA-A*0201-restricted H-Y antigen contains a post-translationally modified cysteine that significantly affects T cell recognition. Immunity 6:273-81, 1997.

  • den Haan JM, Meadows LM, Wang W et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279:1054-7, 1998.

  • Groh V, Li YQ, Cioca D, Hunder NN, Wang W et al. Efficient cross-priming of melanoma, ovarian and breast tumor antigen-specific T cells by dendritic cells sensitized with anti-MICA opsonized tumor cells. Proc Natl Acad Sci USA 102:6461-6, 2005.

  • Wang W, Epler J, Salazar L and Riddell SR. NY-BR-1 is presented by breast cancer cells and recognized by CD8+ cytotoxic T cells. Cancer Reseach 66:6826-6833, 2006


bottom of page